Skip Navigation
Skip to contents

Scientific Program

Filter
SELECT AND VIEW SESSIONS OF YOUR CHOICE
Search

[JS01] Joint Session 01 (Asia Session)

New Era of MPN Treatment

Galaxy Theater
  • March 26 (Thu), 09:00-10:15
  • Sung-Yong Kim (Konkuk University School of Medicine, Korea)
    Hsin-An Hou (National Taiwan University Hospital, Taiwan)
  • 09:00-09:20 Advances and Insights in Molecular Monitoring for Myeloproliferative Neoplasms Hsin-An Hou (National Taiwan University Hospital, Taiwan) 09:20-09:40 Evolving Treatment Paradigms in Early Myelofibrosis Winnie Teo (Alexandra Hospital, Singapore) 09:40-10:00 Optimizing Treatment Strategies in Higher MF and Beyond Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea) 10:00-10:15 Discussion

[SS01] Scientific Session 01

Novel Managements Tools for Hemophilia

Discovery Hall
  • March 26 (Thu), 09:00-10:15
  • Eun Jin Choi (Daegu Catholic University School of Medicine, Korea)
    Jung Woo Han (Yonsei University College of Medicine, Korea)
  • 09:00-09:25 Recent Advances in the Diagnosis and Management of Acquired Hemophilia A Shin Young Hyun (Yonsei University College of Medicine, Korea) 09:25-09:50 Clinical Advances and Challenges in Gene Therapy for Hemophilia Ben Samelson-Jones (The Children's Hospital of Philadelphia, USA) 09:50-10:15 Role of Bispecific Antibody in Hemophilia Claude Négrier (University of Lyon, France)

[SS02] Scientific Session 02

ALL 2026: Shifting Standards and Emerging Innovations

Universe Arena
  • March 26 (Thu), 09:00-10:15
  • Seok Lee (Ewha Womans University College of Medicine, Korea)
    Won Sik Lee (Inje University College of Medicine, Korea)
  • 09:00-09:25 Integration of MRD and Genetics as a Therapeutic Guidepost in ALL Anthony Moorman (Newcastle University, UK) 09:25-09:50 Modern Immunotherapeutics in B-ALL: BiTEs, ADCs, and Beyond Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) 09:50-10:15 Optimizing Frontline Therapy in Ph+ ALL: The Role of Ponatinib and Beyond Nicholas J. Short (The University of Texas MD Anderson Cancer Center, USA)

[ES01] Education Session 01

FOCUS ON: Indolent B-cell Lymphomas

Supernova Stage
  • March 26 (Thu), 09:00-10:15
  • Jeong A Kim (College of Medicine, The Catholic University of Korea, Korea)
    Jeong-Ok Lee (Seoul National University College of Medicine, Korea)
  • 09:00-09:25 Mantle Cell Lymphoma Jaewon Hyung (University of Ulsan College of Medicine, Korea) 09:25-09:50 Chronic Lymphocytic Leukemia Jongheon Jung (National Cancer Center, Korea) 09:50-10:15 Marginal Zone Lymphoma Sang-A Kim (Seoul National University College of Medicine, Korea)

[PL01] Plenary Lecture 01

Galaxy Theater & Discovery Hall
  • March 26 (Thu), 10:30-11:15
  • Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea)
  • 10:30-11:15 What Makes a Stem Cell and How Does It Go Bad John E. Dick (University Health Network, Canada)

[PS01] Presidential Symposium

Galaxy Theater & Discovery Hall
  • March 26 (Thu), 11:15-12:00
  • Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
  • 11:15-12:00 Mechanism-Driven Combination Targeted Therapies for Diffuse Large B-cell Lymphoma Wyndham H. Wilson (National Cancer Institute, USA)

[SY01] Satellite Symposium 01

Roche Korea

Galaxy Theater
  • March 26 (Thu), 12:15-13:05
  • Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
  • 12:15-13:05 Recent Insights on DLBCL Treatment: Focused on Polatuzumab and Glofitamab Matthew Matasar (Rutgers Cancer Institute, USA)

[SY02] Satellite Symposium 02

GC Biopharma

Discovery Hall
  • March 26 (Thu), 12:15-13:05
  • Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
  • 12:15-13:05 Immunoglobulin Replacement in the Era of Cellular and Bispecific Therapies Ja Min Byun (Seoul National University College of Medicine, Korea)

[SY03] Satellite Symposium 03

GlaxoSmithKline

Universe Arena
  • March 26 (Thu), 12:15-13:05
  • Jin Seok Kim (Yonsei University College of Medicine, Korea)
  • 12:15-13:05 Changing the Survival Landscape in RRMM with Novel ADC Sung-Hoon Jung (Chonnam National University Medical School, Korea)

[SY04] Satellite Symposium 04

AbbVie Korea

Supernova Stage
  • March 26 (Thu), 12:15-13:05
  • Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
  • 12:15-13:05 Epcoritamab in 3L+ DLBCL: Updates on Clinical Trial and Real World Data in the Evolving DLBCL Treatment Pathway William Townsend (University College London Hospitals NHS Foundation Trust, UK)

[SY05] Satellite Symposium 05

Novartis Korea

Grand 4+5
  • March 26 (Thu), 12:15-13:05
  • Sung-Hyun Kim (Dong-A University College of Medicine, Korea)
  • 12:15-13:05 Advancing CML Treatment with Clinical Insights on Asciminib Eri Matsuki (Keio University School of Medicine, Japan)

[OP01] Oral Presentation 01

Acute Leukemia 1

Galaxy Theater
  • March 26 (Thu), 13:55-15:10
  • Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)
    Joon Ho Moon (Kyungpook National University School of Medicine, Korea)
  • 13:55-14:07 Development and Internal Validation of a Simple Three-Gene Risk Score for Elderly AML Patients Receiving Nonintensive Therapy Sang-A Kim (Seoul National University Bundang Hospital, Korea) 14:07-14:19 The Impact of RUNX1-RUNX1T1 Transcript Kinetics and Co-Mutation on the Post-Transplant Outcomes in Acute Myeloid Leukemia with t(8;21): A Real-World Study Yi Xia (Peking University People’s Hospital, China) 14:19-14:31 Prognostic Heterogeneity and Treatment Outcomes in TP53 Mutated Acute Myeloid Leukemia: A Prospective Nationwide Multicenter Study Mihee Kim (Chonnam National University Hwasun Hospital, Korea) 14:31-14:43 Comprehensive Prognostic Stratification by Gene Deletion Profiles in Adult Patients with BCP-ALL: Distinct Biological and Clinical Implications in Ph-Negative and Ph-Positive ALL Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) 14:43-14:55 Revealing Subtype-Specific Immunophenotypic and Cytogenetic Patterns That Improve Detection of Measurable Residual Disease in B-Lymphoblastic Leukemia Ju Hyeong Lee (Seoul National University Hospital, Korea) 14:55-15:07 Impact of End-of-Induction Measurable Residual Disease Status across Cytogenetic Subtypes among Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia: Do TCF3::PBX1 Patients Warrant Altered Risk Stratification and Treatment? Karthik Bommannan Bommannan Kuppuraju (Cancer Institute (W.I.A), India)

[OP02] Oral Presentation 02

Myelodysplastic Syndrome & Myeloproliferative Neoplasm

Discovery Hall
  • March 26 (Thu), 13:55-15:10
  • Dong-Yeop Shin (Seoul National University College of Medicine, Korea)
    Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)
  • 13:55-14:07 ASXL1 Mutation Status Influences the Response to Retinoid-Based Epigenetic Differentiation Therapy in MDS/AML Lukasz Szymanski (Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Poland) 14:07-14:19 TP53 Allelic State Defines Infection Susceptibility in Myelodysplastic Syndrome and Acute Myeloid Leukemia Junshik Hong (Seoul National University Hospital, Korea) 14:19-14:31 Therapy-Related Myelodysplastic Syndromes: Clinical Characteristics and Real-World Treatment Outcomes from a Single-Center Cohort Yunsuk Choi (Asan Medical Center, University of Ulsan College of Medicine, Korea) 14:31-14:43 Individualized Decitabine Dosing for Post-HSCT Maintenance in MDS: Long-Term Outcomes from the PODAC Trial and Matched Controls Hohyung Nam (Seoul St. Mary's Hospital, Korea) 14:43-14:55 Ropeginterferon Dose-Escalation Strategies in PV: A Systematic Review and Meta-Analysis Seug Yun Yoon (Soonchunhyang University Seoul Hospital, Korea) 14:55-15:07 Long-Term Molecular Response to Ropeginterferon alfa-2b and Clinical Validation of qPCR for Low-Level JAK2 Monitoring in Polycythemia Vera So Yeon Park (Seoul St. Mary's Hospital, Korea)

[OP03] Oral Presentation 03

Lymphoma

Universe Arena
  • March 26 (Thu), 13:55-15:10
  • Young Hoon Park (Ewha Womans University College of Medicine, Korea)
    Yoon Seok Choi (Korea University College of Medicine, Korea)
  • 13:55-14:07 Phase II Study of Lenalidomide Maintenance after Rituximab-Methotrexate-Based Induction Therapy in Primary CNS Lymphoma Ji Yun Lee (Seoul National University Bundang Hospital, Korea) 14:07-14:19 Phase 1 Study of GCC2005, an Allogeneic CD5-Directed CAR-NK Therapy, for Patients with Relapsed/Refractory NK/T-cell Malignancies Dok Hyun Yoon (Asan Medical Center, University of Ulsan College of Medicine, Korea) 14:19-14:31 Treatment Patterns and Survival Outcomes in Patients with Mantle Cell Lymphoma: Updated Interim Report of the Asia-Pacific Multinational Prospective Registry Study Hyungwoo Cho (Asan Medical Center, University of Ulsan College of Medicine, Korea) 14:31-14:43 Clinical and Functional Impact of CD19-Positive Extracellular Vesicles in CD19 CAR-T Treated Diffuse Large B-cell Lymphoma Bon Park (Sungkyunkwan University, Korea) 14:43-14:55 Longitudinal Whole Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as Predictors of Treatment Outcome in Newly Diagnosed Chronic Lymphocytic Leukemia Treated with Chlorambucil-Obinutuzumab Ho Cheol Jang (Chonnam National University Hwasun Hospital, Korea) 14:55-15:07 The Role of Maintenance Therapy with PD-1 Inhibitors after Autologous HSCT in Patients with Classical Hodgkin Lymphoma at High Risk of Relapse and Progression Ekaterina Fastova (National Medical Research Center for Hematology, Russia)

[OP04] Oral Presentation 04

General Hematology

Supernova Stage
  • March 26 (Thu), 13:55-15:10
  • Yoon Hwan Chang (Seoul National University College of Medicine, Korea)
    Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)
  • 13:55-14:07 Long-Term Outcomes and Inhibitor Relapse Following Immune Tolerance Induction in Severe Hemophilia A Patients with Inhibitors: A Prospective Multicenter Study Zhengping Li (Beijing Children's Hospital, Capital Medical University, China) 14:07-14:19 A Reference Laboratory’s Experience with 16 Unstable Hemoglobin Variants over 14 Years: Diagnostic Clues, Pitfalls, and the Role of Sequencing Prashant Sharma (Postgraduate Institute of Medical Education and Research, India) 14:19-14:31 Efficacy of HLA-Matched Platelet Transfusion and Its Predictors in Platelet Refractory Patients with Hematologic Malignancies Jiwoo Lee (Seoul National University Hospital, Korea) 14:31-14:43 Impact of Anti-CD38 Monoclonal Antibody Therapy on Pretransfusion Testing and Transfusion Strategies in Multiple Myeloma Patients at an Eastern Taiwan Medical Center Min-Hsuan Lan (Tzu Chi University, Tzu Chi Hospital, Taiwan) 14:43-14:55 Artificial Intelligence-Optimized Monocytosis Workflow: Transforming Early Detection of Hematologic Malignancies in Automated Hematology Systems Yama Sirly Putri (Faculty of Medicine Indo Global Mandiri University, Indonesia) 14:55-15:07 Clinical Effectiveness and Bleeding Outcomes of Edoxaban for Cancer-Associated Venous Thromboembolism in Korean Patients: A Prospective, Multicenter, Single-Arm, Observational Cohort Study Ho-Young Yhim (Jeonbuk National University Medical School, Korea)

[JS02] Joint Session 02 (MOU Session)

The Present and Future of Bone Marrow Failure Syndrome in Asia

Galaxy Theater
  • March 26 (Thu), 15:25-16:40
  • Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
    Ponlapat Rojnuckarin (Chulalongkorn University, Thailand)
  • 15:25-15:45 The Current State of Transplantation for Aplastic Anemia in Vietnam Han Viet Trung (Bach Mai Hospital, Vietnam) 15:45-16:05 Recent Update of the Treatment of Aplastic Anemia in Thailand Ponlapat Rojnuckarin (Chulalongkorn University, Thailand) 16:05-16:25 PNH Management in Korea: Therapeutic Options, Access and Real-World Outcomes Silvia Park (College of Medicine, The Catholic University of Korea, Korea) 16:25-16:40 Discussion

[SS03] Scientific Session 03

Geriatric Hematology

Discovery Hall
  • March 26 (Thu), 15:25-16:40
  • ByungSoo Kim (Korea University College of Medicine, Korea)
    Sangkyun Sohn (Kyungpook National University School of Medicine, Korea)
  • 15:25-15:50 Integrating Comprehensive Geriatric Assessment into Hematology Practice: Identifying Frailty and Optimizing Care for Older Adults Jung-Yeon Choi (Seoul National University Bundang Hospital, Korea) 15:50-16:15 Redefining Risk in Elderly AML: A Geriatric Assessment-Based Approach Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) 16:15-16:40 Psycho-Oncological Interventions in Geriatric Hematology: Enhancing Quality of Life Juhee Cho (Samsung Comprehensive Cancer Center, Sungkyunkwan University, Korea)

[SS04] Scientific Session 04

Next-Generation Cell Therapies: In Vivo CAR Engineering, Myeloid Modulation, and Beyond

Universe Arena
  • March 26 (Thu), 15:25-16:40
  • Hyoung Jin Kang (Seoul National University College of Medicine, Korea)
    Young Rok Do (Keimyung University School of Medicine, Korea)
  • 15:25-15:50 Engineered NK Cells for Optimal Anti-Tumor Immunotherapy Challice Bonifant (Johns Hopkins University School of Medicine, USA) 15:50-16:15 Lessons from Hemophagocytic Lymphohistiocytosis: Taming the Cytokine Storm in CAR-T Cell Therapy Michael B. Jordan (Cincinnati Children’s Hospital Medical Center, USA) 16:15-16:40 Tumor-Marrow Axis: Myeloid Reprogramming from Suppression to Activation Seunghee Kim-Schulze (Icahn School of Medicine at Mount Sinai, USA)

[ES02] Education Session 02

Recent Advances in Acute Leukemia

Supernova Stage
  • March 26 (Thu), 15:25-16:40
  • Chul Won Choi (Korea University College of Medicine, Korea)
    Jae-Sook Ahn (Chonnam National University Medical School, Korea)
  • 15:25-15:50 FLT3-Positive AML Ik-Chan Song (Chungnam National University College of Medicine, Korea) 15:50-16:15 B-cell ALL with HIgh Risk Features in Adults Dong Won Baek (Kyungpook National University School of Medicine, Korea) 16:15-16:40 Understanding and Clinical Approach to Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Hee Young Ju (Sungkyunkwan University School of Medicine, Korea)

[SS05] Scientific Session 05

MDS: Perspectives from Multiple Viewpoints

Galaxy Theater
  • March 26 (Thu), 16:55-18:10
  • Je-Hwan Lee (University of Ulsan College of Medicine, Korea)
    Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea)
  • 16:55-17:20 Insights into DDX41 Mutations: Relatively Common Genetic Aberrations in Korean MDS Patients Hongtae Kim (Ulsan National Institute of Science and Technology (UNIST), Korea) 17:20-17:45 Few Drug Approvals in MDS: Lessons and Insights from a Decade of Clinical Trials Maximilian Stahl (Yale University School of Medicine, USA) 17:45-18:10 Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes Valeria Santini (University of Florence, Italy)

[SS06] Scientific Session 06

Focus on Telomeres in Hematology

Discovery Hall
  • March 26 (Thu), 16:55-18:10
  • Ho Joon Im (University of Ulsan College of Medicine, Korea)
    Hyeon Jin Park (National Cancer Center, Korea)
  • 16:55-17:20 Recent Advances in the Genetics of Telomere Biology Disorders Sharon A. Savage (National Institutes of Health, USA) 17:20-17:45 Clonal Hematopoiesis in the Short Telomere Syndromes Kristen E. Schratz (Johns Hopkins University School of Medicine, USA) 17:45-18:10 Current Status of Telomere Biology Disorders in Inherited Bone Marrow Failure Inderjeet Dokal (Queen Mary University of London, UK)

[SS07] Scientific Session 07

Advancing Immunotherapy in Multiple Myeloma: Mechanisms and Next-Generation Strategies

Universe Arena
  • March 26 (Thu), 16:55-18:10
  • Jin Seok Kim (Yonsei University College of Medicine, Korea)
    Seong Hyun Jeong (Ajou University School of Medicine, Korea)
  • 16:55-17:20 Next-Generation Effector Cells in Myeloma Immunotherapy Hyunsoo Cho (Seoul National University College of Medicine, Korea) 17:20-17:45 Natural Killer Cell-Based Immunotherapy in Multiple Myeloma Seung-Hwan Lee (University of Ottawa, Canada) 17:45-18:10 Preclinical Optimization of T Cell Redirected Therapy Marta Chesi (Mayo Clinic, USA)

[ES03] Education Session 03

Integrated Laboratory Perspectives in Hematologic Malignancies: From Initial Workup to Transplantation

Supernova Stage
  • March 26 (Thu), 16:55-18:10
  • Hyun Kyung Kim (Seoul National University College of Medicine, Korea)
    Jihyang Im (College of Medicine, The Catholic University of Korea, Korea)
  • 16:55-17:20 Procedures and Interpretation of Bone Marrow Examination Seung Yeob Lee (Jeonbuk National University Medical School, Korea) 17:20-17:45 Diagnostic and Monitoring Approaches Focused on Minimal Residual Disease Miyoung Kim (University of Ulsan College of Medicine, Korea) 17:45-18:10 Laboratory Tests Performed in Blood Bank before and after Hematopoietic Stem Cell Transplantation Dong Wook Jekarl (College of Medicine, The Catholic University of Korea, Korea)

[JS03] Joint Session 03 (ASH-KSH)

Emerging Therapeutic Landscape for Unfit AML

Galaxy Theater
  • March 27 (Fri), 09:00-10:15
  • Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)
    Pamela S. Becker (City of Hope, USA)
  • 09:00-09:15 Multi-Omic Precision Medicine including Functional Drug Screening to Optimize Treatment for Acute Myeloid Leukemia Pamela S. Becker (City of Hope, USA) 09:15-09:30 Novel Immunotherapeutic Strategies: Preclinical Insights Ji Eun Jang (Yonsei University College of Medicine, Korea) 09:30-09:45 Developing Next-Generation Cell Therapy Approaches for AML Paulina Velasquez (St. Jude Children’s Research Hospital, USA) 09:45-10:00 Emerging Ex-vivo Drug Sensitivity Platforms Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea) 10:00-10:15 Discussion

[SS08] Scientific Session 08

Microbiome-Driven Precision Medicine in Hematology

Discovery Hall
  • March 27 (Fri), 09:00-10:15
  • Myung Geun Shin (Chonnam National University Medical School, Korea)
    Hyery Kim (University of Ulsan College of Medicine, Korea)
  • 09:00-09:25 Microbiome-Driven Precision Medicine in CAR-T Cell Therapy in Hematology Christoph K. Stein-Thoeringer (University Clinic Tübingen, Germany) 09:25-09:50 Gut Microbiome as a Predictive Biomarker and Emerging Intervention Target in DLBCL Woorim Kang (Kangwon National University, Korea) 09:50-10:15 Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy Jonathan U. Peled (Memorial Sloan Kettering Cancer Center, USA)

[SS09] Scientific Session 09

Future of Immunotherapy in DLBCL

Universe Arena
  • March 27 (Fri), 09:00-10:15
  • Jae-Yong Kwak (Jeonbuk National University Medical School, Korea)
    Sung Yong Oh (Dong-A University College of Medicine, Korea)
  • 09:00-09:25 A Personalized Approach to Immune Therapies for Cancer: One Drug, One Patient Larry W. Kwak (City of Hope, USA) 09:25-09:50 Paradigm Shift in the Treatment of Diffuse Large B-cell Lymphoma: The Era of Bispecific Antibodies Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) 09:50-10:15 Toward a Paradigm Shift in Personalized Therapies for DLBCL Using Liquid Biopsies Ash A. Alizadeh (Stanford University, USA)

[ES04] Education Session 04

Understanding Anemia

Supernova Stage
  • March 27 (Fri), 09:00-10:15
  • Eun Sun Yoo (Ewha Womans University College of Medicine, Korea)
    Jun Eun Park (Korea University College of Medicine, Korea)
  • 09:00-09:25 Iron Deficiency & Iron Metabolism Jeong-Ok Lee (Seoul National University College of Medicine, Korea) 09:25-09:50 Hereditary Hemolytic Anemia Heewon Chueh (Inje University College of Medicine, Korea) 09:50-10:15 Cold Agglutinin Disease Dae-Ho Choi (Sungkyunkwan University School of Medicine, Korea)

[PL02] Plenary Lecture 02

Galaxy Theater & Discovery Hall
  • March 27 (Fri), 10:30-11:15
  • Deog-Yeon Jo (Chungnam National University College of Medicine, Korea)
  • 10:30-11:15 The Past, Present and Future of Hematopoietic Stem Cell Gene Therapies Cynthia E. Dunbar (National Institutes of Health, USA)

[SY06] Satellite Symposium 06

GlaxoSmithKline

Galaxy Theater
  • March 27 (Fri), 12:15-13:05
  • Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
  • 12:15-13:05 Triple Targeting in Myelofibrosis with Momelotinib: Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)

[SY07] Satellite Symposium 07

DKSH KOREA

Discovery Hall
  • March 27 (Fri), 12:15-13:05
  • Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
  • 12:15-13:05 Clinical Evidence of Romiplostim in Aplastic Anemia: Korean Expert Recommendations Silvia Park (College of Medicine, The Catholic University of Korea, Korea)

[SY08] Satellite Symposium 08

Johnson & Johnson Innovative Medicine

Universe Arena
  • March 27 (Fri), 12:15-13:05
  • Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
  • 12:15-13:05 Daratumumab in the Emerging Landscape of Functional High-Risk Multiple Myeloma Andrew Spencer (Alfred Hospital, Australia)

[SY09] Satellite Symposium 09

Gilead Sciences, Inc.

Supernova Stage
  • March 27 (Fri), 12:15-13:05
  • Deok Hwan Yang (Chonnam National University Medical School, Korea)
  • 12:15-13:05 Early CAR-T Intervention in DLBCL: Clinical Advances and Real-World Effectiveness of Axi-cel Mark Dowling (Peter MacCallum Cancer Centre, Australia)

[SY10] Satellite Symposium 10

BMS Pharmaceutical Korea

Grand 4+5
  • March 27 (Fri), 12:15-13:05
  • Dong-Wook Kim (Eulji University School of Medicine, Korea)
  • 12:15-13:05 How to Optimize CML Treatment in 2026: ELN 2025 and Molecular Guidance Elias Jabbour (MD Anderson Cancer Center, USA)

[OP05] Oral Presentation 05

Acute Leukemia 2

Galaxy Theater
  • March 27 (Fri), 13:35-14:50
  • Yong Park (Korea University College of Medicine, Korea)
    Hee Young Ju (Sungkyunkwan University School of Medicine, Korea)
  • 13:35-13:47 Development of Preclinical Leukemic Models for Acquired Resistance to a FLT3 Inhibitor Eun-Ji Choi (Asan Medical Center, University of Ulsan College of Medicine, Korea) 13:47-13:59 The Effect of Allogeneic HSCT on Pediatric nonDown Syndrome AMKL: Results from a Multicenter CALD-AMKL-18 Trial Shengqin Cheng (Children's Hospital of Soochow University, China) 13:59-14:11 Clinical Characteristics and Prognostic Implications according to Partner Genes in Adult Acute Myeloid Leukemia with KMT2A Rearrangement So Yeon Park (Seoul St. Mary's Hospital, Korea) 14:11-14:23 Combinatorial Cell-Surface Markers Derived from Single-Cell Transcriptomics Enable Precise Discrimination of LSCs from HSCs in Acute Myeloid Leukemia Smeeta Gajendra (All India Institute of Medical Sciences, India) 14:23-14:35 Refining Genomic Risk Stratification in Adult Patients with Ph-Negative All by Functional Classification of IKZF1 Deletions Seung-Hwan Lee (Seoul St. Mary’s Hospital, Korea) 14:35-14:47 Immunotargeted Therapy Challenges the Role of Second Transplantation after Post-Transplant Relapse in Adult Patients with B-ALL : A Contemporary Real-World Analysis Jaehyun Ahn (Seoul St. Mary’s Hospital, Korea)

[OP06] Oral Presentation 06

Hematopoietic Stem Cell Transplantation / Cellular Therapy

Discovery Hall
  • March 27 (Fri), 13:35-14:50
  • Byung Su Kim (College of Medicine, The Catholic University of Korea, Korea)
    Kyung Taek Hong (Seoul National University College of Medicine, Korea)
  • 13:35-13:47 Clinical Benefits of Ruxolitinib in Moderate-to-Severe CRS: Reduced Severe ICANS and Steroid Use with Preserved Survival after Pediatric CAR-T Therapy Qi Ji (Children’s Hospital of Soochow University, Jiangsu Province, China) 13:47-13:59 CD19 CAR-T Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): The First Investigator-Initiated Trial with Point-of-Care CAR-T Manufacturing in Korea Hyoung Jin Kang (Seoul National University College of Medicine, Korea) 13:59-14:11 Post-Autologous Stem Cell Transplantation Cytokine-Induced Killer Cell Infusion as a Post-Remission Strategy in High-Risk Lymphoma Gi June Min (Seoul St. Mary’s Hospital, Korea) 14:11-14:23 Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Severe Aplastic Anemia: A Single-Center Study Hyun Jin Park (Seoul National University College of Medicine, Korea) 14:23-14:35 Vedolizumab for Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Real-World VAST Study Yi Xia (Peking University People’s Hospital, China) 14:35-14:47 Distinct Dynamics of Regulatory T Cells after Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide vs. Antithymocyte Globulin Eun-Ji Choi (Asan Medical Center, University of Ulsan College of Medicine, Korea)

[OP07] Oral Presentation 07

Multiple Myeloma

Universe Arena
  • March 27 (Fri), 13:35-14:50
  • Min Kyoung Kim (Yeungnam University College of Medicine, Korea)
    Jun Ho Yi (Sungkyunkwan University School of Medicine, Korea)
  • 13:35-13:47 Prevalence and Prognostic Impact of 1p32 Deletion in Newly Diagnosed Multiple Myeloma Sreejesh Sreedharanunni (Postgraduate Institute of Medical Education and Research, India) 13:47-13:59 Single Cell Transcriptomic Profiling of Bone Marrow Reveals Progressive T Cell Exhaustion and Myeloid Activation in Multiple Myeloma and Plasma Cell Leukemia Ho Cheol Jang (Chonnam National University Hwasun Hospital, Korea) 13:59-14:11 Deep Hematologic Response Overrides the Impact of Treatment Modality on Progression-Free Survival in AL Amyloidosis: A Korean Multicenter Study Joon Young Hur (Asan Medical Center, Korea) 14:11-14:23 Mezigdomide Enhances BCMAxCD3 T-cell Engager-Induced Cytotoxicity Under High Target Cell Load Conditions Hyunsoo Cho (Seoul National University College of Medicine, Korea) 14:23-14:35 Prospective, Multicenter Phase II Study to Evaluate Clinical Benefit of Reduced-Dose Lenalidomide and Dexamethasone Based on Frailty Stratification in Elderly Unfit Patients with Newly Diagnosed Multiple Myeloma Sung-Hoon Jung (Chonnam National University Medical School, Korea) 14:35-14:47 Decoding the Role of TANGO1 in Myeloma Proteostasis and Therapeutic Vulnerability Ji Eun Lee (Yonsei University College of Medicine, Seoul National University, Korea)

[OP08] Oral Presentation 08

Cytopenia & Bone Marrow Failure

Supernova Stage
  • March 27 (Fri), 13:35-14:50
  • Young Kyung Lee (Hallym University College of Medicine, Korea)
    Yeon Jung Lim (Chungnam National University College of Medicine, Korea)
  • 13:35-13:47 Diagnostic Errors of Beta-Thalassemia by Hemoglobin Variants with Elevated Hb A2 Levels and Co-Migration with Hb F Kritsada Singha (Khon Kaen University, Mahasarakham University, Thailand) 13:47-13:59 Expanding Genetic Landscape of Inherited Bone Marrow Failure Syndromes: Insights from the Canadian Inherited Marrow Failure Registry (CIMFR) (2001-2023) Ye Jee Shim (Kyungpook National University Children's Hospital, Korea) 13:59-14:11 Integrative Transcriptomic Profiling Reveals Shared mRNA and lncRNA Signatures in Pediatric Bone Marrow Failure Syndromes Jong-Mi Lee (Seoul St. Mary’s Hospital, Korea) 14:11-14:23 Umbilical Cord Blood Transplantation for Primary Immunodeficiency in Children: A Ten-Year Single-Center Clinical Analysis Qingwei Wang (Children's Hospital of Soochow University, Jiangsu Provincial Center for Pediatric Hematology and Oncology, China) 14:23-14:35 First-Line Hetrombopag Combined with Immunosuppressive Therapy for Pediatric Severe Aplastic Anemia: A Prospective Randomized Controlled Trial Lingling Fu (Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, China) 14:35-14:47 Emergency Myelopoiesis and Monocyte Reprogramming Underlie Immune Dysregulation in Lymphoma-Associated Secondary Hemophagocytic Lymphohistiocytosis Jeong-Eun Kwak (Seoul National University Hospital, Korea)

[JS04] Joint Session 04 (EHA-KSH)

From Operations to Evidence: CAR T-cell Therapy Through Registry and CNS Lymphoma Practice

Galaxy Theater
  • March 27 (Fri), 15:05-16:20
  • Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
    Andrés J. M. Ferreri (University Vita-Salute San Raffaele, Italy)
  • 15:05-15:20 Operational Wisdom in CAR T Jürgen Kuball (University Medical Center Utrecht, The Netherlands) 15:20-15:35 Korean CAR T-cell Registry: Inauguration and the Current Status of CAR T-cell Therapy in Korea Ji Hyun Lee (Dong-A University College of Medicine, Korea) 15:35-15:50 CAR T-cell Therapy for Primary and Secondary CNS Lymphomas Andrés J. M. Ferreri (University Vita-Salute San Raffaele, Italy) 15:50-16:05 CAR T-cell Therapy in Primary and Secondary CNS Lymphomas in Korea Hyungwoo Cho (Asan Medical Center, University of Ulsan College of Medicine, Korea) 16:05-16:20 Discussion

[SS10] Scientific Session 10

Pediatric Malignancies: From Patients to Survivors

Discovery Hall
  • March 27 (Fri), 15:05-16:20
  • Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)
    Hyoung Soo Choi (Seoul National University College of Medicine, Korea)
  • 15:05-15:30 Genomics and Transplant Strategies in Pediatric Myeloid Malignancies Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea) 15:30-15:55 Virus-Specific and Next-Generation T-cell Therapy in Pediatric Hematologic Malignancy Catherine M. Bollard (Children’s National Hospital and The George Washington University, USA) 15:55-16:20 Cancer Survivorship after the Cure of Childhood Blood Cancers: Risk Based Surveillance Sharon M. Castellino (Emory University School of Medicine, USA)

[SS11] Scientific Session 11

Transforming the Therapeutic Landscape of AML: From Biology to Targeted Therapies

Universe Arena
  • March 27 (Fri), 15:05-16:20
  • Chul Won Jung (Sungkyunkwan University School of Medicine, Korea)
    Il-Hoan Oh (College of Medicine, The Catholic University of Korea, Korea)
  • 15:05-15:30 Stem Cells in Human AML Ravindra Majeti (Stanford University, USA) 15:30-15:55 Evolving Frontiers in Targeted Therapy: Menin Inhibition in AML Eytan M. Stein (Memorial Sloan Kettering Cancer Center, USA) 15:55-16:20 HMA + Venetoclax + Targeted Agents: Clinical Evidence and Future of Triplet Therapy in AML Tapan Kadia (The University of Texas MD Anderson Cancer Center, USA)

[ES05] Education Session 05

Big Data and AI in Hematology Research

Supernova Stage
  • March 27 (Fri), 15:05-16:20
  • Sung-Hyun Kim (Dong-A University College of Medicine, Korea)
    Dae Sik Kim (Korea University College of Medicine, Korea)
  • 15:05-15:30 Real-World Effectiveness of Immunotherapy in Hematologic Malignancies: Evidence from Big Data Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea) 15:30-15:55 Digital Healthcare Innovation: Real-World Applications of Big Data and AI Yoon Sup Choi (Digital Healthcare Partners (DHP), Korea) 15:55-16:20 Wise Hematology Life: Practical Integration of Large Language Models and Agentic AI into Clinical Research Jeong-Moo Lee (Ewha Womans University College of Medicine, Korea)

[SS12] Scientific Session 12

Expanding Therapeutic Horizons in ITP and TTP

Discovery Hall
  • March 27 (Fri), 16:35-17:50
  • Dae Chul Jeong (College of Medicine, The Catholic University of Korea, Korea)
    Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)
  • 16:35-17:00 Real World Long Term TPO-RA: Sustaining Remission or Time to Stop? Nichola Cooper (Imperial College Health Care NHS Trust, UK) 17:00-17:25 A New Chapter in ITP Management - Updated Trials Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea) 17:25-17:50 Caplacizumab and the Changing Landscape of TTP Management Shruti Chaturvedi (Johns Hopkins University School of Medicine, USA)

[SS13] Scientific Session 13

Other Plasma Cell Disorders: From Diagnosis to Mechanistic Insights

Universe Arena
  • March 27 (Fri), 16:35-17:50
  • Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
    Ho Sup Lee (Kosin University College of Medicine, Korea)
  • 16:35-17:00 AL Amyloidosis: A Comprehensive Update from Fundamentals to Emerging Therapies Efstathios Kastritis (National and Kapodistrian University of Athens, Greece) 17:00-17:25 Monoclonal Gammopathy and the Kidney: A Comprehensive Approach to MGRS Nelson Leung (Mayo Clinic, USA) 17:25-17:50 Novel Biological and Clinical Insights into POEMS Syndrome: Pathophysiology and Real-World Treatment Outcomes from Japan Emiko Sakaida (Chiba University Hospital, Japan)

[ES06] Education Session 06

Toxicity Masterclass: Managing CRS, Cytopenia, and Infections in T Cell Engaging Therapies

Supernova Stage
  • March 27 (Fri), 16:35-17:50
  • Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea)
    Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)
  • 16:35-17:00 CRS and ICANS: Early Detection and Personalized Management Jinchul Kim (Inha University College of Medicine, Korea) 17:00-17:25 Prolonged Cytopenia after TCEs: Mechanisms, Biomarkers, and Risk Stratification Sang Eun Yoon (Sungkyunkwan University School of Medicine, Korea) 17:25-17:50 Preventing Infections in TCEs: Risk Stratification and Prophylaxis Ja Min Byun (Seoul National University College of Medicine, Korea)

[JS05] Joint Session 05 (Asia Session)

Cross-Border Insights in NK/T-cell and T-cell Lymphoma: Perspectives from Japan, China, and Korea

Galaxy Theater
  • March 28 (Sat), 09:00-10:15
  • Deok Hwan Yang (Chonnam National University Medical School, Korea)
    Motoko Yamaguchi (Mie University Graduate School of Medicine, Japan)
  • 09:00-09:20 Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan Motoko Yamaguchi (Mie University Graduate School of Medicine, Japan) 09:20-09:40 Advances in the Diagnosis and Treatment of NK/T-cell Lymphoma: Perspectives and Team Experience Huangming Hong (Sichuan Cancer Hospital, China) 09:40-10:10 Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) 10:00-10:15 Discussion

[SS14] Scientific Session 14

Germline Variants and Hematologic Malignancies: Current Understanding and Clinical Implications

Discovery Hall
  • March 28 (Sat), 09:00-10:15
  • Seongsoo Jang (University of Ulsan College of Medicine, Korea)
    Myung-Hyun Nam (Korea University College of Medicine, Korea)
  • 09:00-09:25 Ethnic Disparities in Germline Variants of Myeloid Malignancies Young-Uk Cho (University of Ulsan College of Medicine, Korea) 09:25-09:50 Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management Marc H.G.P. Raaijmakers (Erasmus MC Cancer Institute, The Netherlands) 09:50-10:15 Germline Predisposition Genes in Lymphoid Malignancies Susan L. Slager (Mayo Clinic, USA)

[SS15] Scientific Session 15

Exploring the Map of CML: Beyond BCR::ABL1

Universe Arena
  • March 28 (Sat), 09:00-10:15
  • Dong-Wook Kim (Eulji University School of Medicine, Korea)
    Hawk Kim (Ewha Womans University College of Medicine, Korea)
  • 09:00-09:25 Immunological Landscape of CML Kyung-Mi Lee (Korea University College of Medicine, Korea) 09:25-09:50 Translating Single-Cell Biology into Clinically Actionable Protein Biomarkers in CML Sin Tiong Ong (Duke-NUS Medical School, Singapore) 09:50-10:15 Drug Combination to Overcome Resistance in CML Delphine Rea (Saint-Louis University Hospital, France)

[ES07] Education Session 07

Preventive and Supportive Approaches in Hematologic Malignancies

Supernova Stage
  • March 28 (Sat), 09:00-10:15
  • Joon Seong Park (Ajou University School of Medicine, Korea)
    Hyo Jung Kim (Hallym University College of Medicine, Korea)
  • 09:00-09:25 Vaccination and Infection Prevention Seong Jin Choi (Seoul National University College of Medicine, Korea) 09:25-09:50 Cardiotoxicity: Risk Assessment and Prevention Hyukjin Park (Chonnam National University Medical School, Korea) 09:50-10:15 Chemotherapy-Induced Peripheral Neuropathy Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea)

[PL03] Plenary Lecture 03

Galaxy Theater & Discovery Hall
  • March 28 (Sat), 10:30-11:15
  • Je-Jung Lee (Chonnam National University Medical School, Korea)
  • 10:30-11:15 High-Risk Multiple Myeloma in 2026: Early Intervention, MRD-Driven Therapy, and Beyond Philippe Moreau (University Hospital of Nantes, France)

Go top

Go top

Hosted by
Supported by